Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration

Prince of Songkla University

Status: Completed

Conditions: Age-related Macular Degeneration

Treatments: Drug: ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00539734

50/362-003-2

Details and patient eligibility

About

Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.

Full description

The functional changes of the retina can be recorded by an electroretinography (ERG).

Enrollment: 25 patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 45 years and above
• Clinical diagnosis of wet AMD
• First injection of ranibizumab protocol
• Best corrected visual acuity 20/32 - 20/320
• Consent form obtained

Exclusion criteria

• Previously treated wet AMD patients
• Patients with other ocular diseases which can cause abnormal ERG such as glaucoma, uveitis or retinitis pigmentosa, etc.
• Pregnancy
• History of seizure

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)